Literature DB >> 6608335

Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. I. Enhanced response in depression and mania.

H Y Meltzer, B Umberkoman-Wiita, A Robertson, B J Tricou, M Lowy, R Perline.   

Abstract

The serum cortisol concentration following administration of 5-hydroxytryptophan (5-HTP), 200 mg orally, a precursor of serotonin (5-HT), was significantly greater in unmedicated depressed and manic patients than in normal controls. Increases in serum cortisol levels greater than 5 micrograms/dL were significantly more frequent in both unmedicated depressed and manic patients than in the normal controls. There was significant test-retest reliability. Baseline serum cortisol concentration correlated negatively with the cortisol response to 5-HTP in normal controls. These results suggest increased 5-HT receptor sensitivity may be present, possibly in the hypothalamus or pituitary, in some patients with affective disorders. These results are consistent with the hypothesis that decreased serotonergic activity, which would be expected to produce increased 5-HT receptor sensitivity, may be present in both depression and mania.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6608335     DOI: 10.1001/archpsyc.1984.01790150056009

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  19 in total

1.  Heterologous supersensitization between serotonin2 and alpha 2-adrenergic receptor-mediated intracellular calcium mobilization in human platelets.

Authors:  A Kagaya; M Mikuni; H Yamamoto; S Muraoka; S Yamawaki; K Takahashi
Journal:  J Neural Transm Gen Sect       Date:  1992

Review 2.  The 5-HT receptor--G-protein--effector system complex in depression. I. Effect of glucocorticoids.

Authors:  K P Lesch; B Lerer
Journal:  J Neural Transm Gen Sect       Date:  1991

3.  The effect of lithium on 5-HT-mediated neuroendocrine responses and platelet 5-HT receptors.

Authors:  P W Glue; P J Cowen; D J Nutt; T Kolakowska; D G Grahame-Smith
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  Serotonin but not norepinephrine-induced calcium mobilization of platelets is enhanced in affective disorders.

Authors:  M Mikuni; A Kagaya; K Takahashi; H Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 5.  Lithium and serotonin function: implications for the serotonin hypothesis of depression.

Authors:  L H Price; D S Charney; P L Delgado; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

6.  Cyclic GMP generation mediated by 5-HT-2 receptors via nitric oxide-dependent pathway and its effect on the desensitization of 5-HT-2 receptors in C6 glioma cells.

Authors:  A Kagaya; N Motohashi; A Kugaya; T Yamaji; T Hayashi; Y Okamoto; H Shinno; M Takebayashi; Y Uchitomi; S Yamawaki
Journal:  J Neural Transm Gen Sect       Date:  1995

7.  Tryptophan depletion reduces right inferior prefrontal activation during response inhibition in fast, event-related fMRI.

Authors:  Katya Rubia; Francis Lee; Anthony J Cleare; Nigel Tunstall; Cynthia H Y Fu; Michael Brammer; Phillip McGuire
Journal:  Psychopharmacology (Berl)       Date:  2005-01-26       Impact factor: 4.530

Review 8.  Corticosteroid-serotonin interactions in depression: a review of the human evidence.

Authors:  Richard J Porter; Peter Gallagher; Stuart Watson; Allan H Young
Journal:  Psychopharmacology (Berl)       Date:  2004-03-09       Impact factor: 4.530

9.  Effects of short-term administration of valproate on serotonin-1A and dopamine receptor function in healthy human subjects.

Authors:  Nicholas J Delva; Deborah L Brooks; Michael Franklin; Khalid al-Said; Emily R Hawken; Zul Merali; J Stuart Lawson; Arun V Ravindran
Journal:  J Psychiatry Neurosci       Date:  2002-11       Impact factor: 6.186

10.  Effect of pindolol on the L-5-HTP-induced increase in plasma prolactin and cortisol concentrations in man.

Authors:  H Y Meltzer; M Maes
Journal:  Psychopharmacology (Berl)       Date:  1994-05       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.